

57. (New) The method of claim 33, wherein the recombinant amyloid fibrils comprise recombinant protein or polypeptide.

### **REMARKS**

#### **Status of the Claims**

Claims 1-3 and 32-57 are pending in the present application. Claims 4-31 have been cancelled. Claims 1-3 have been amended. New claims 32-57 have been added. Thus, claims 1-3 and 32-57 are pending before the Examiner for consideration.

#### **Amendments to the Claims**

Claims 1-3 have been amended to more particularly point out and more distinctly claim Applicants' invention. Support for the amendment to claim 1 can be found in paragraph 132 and in claim 1 as originally filed. Support for the amendment to claim 2 can be found in claim 2 as originally filed and in paragraph 11, lines 4 and 5. Support for the amendment to claim 3 can be found in claim 3 as originally filed.

Support for new claims 32-57 is summarized in the table.

Claim(s)	Support
32	Paragraph 79
33, 57	Paragraph 80
34	Paragraph 78
35	Paragraph 74
36	Paragraph 74
37	Paragraphs 5 and 78
38	Paragraph 78
39, 51	Paragraph 22
40, 52	Paragraph 89
41-45	Paragraph 76

46	Claim 3 as originally filed
47, 48, 49	Paragraph 86
50	Claim 2 as originally filed
53	Claims 2 and 3 as originally filed
54, 55	Paragraph 86
56	Paragraph 74

Rejection of Claims 1-3 Under 35 U.S.C. § 112

Claims 1-3 are rejected under 35 U.S.C. § 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim Applicants' invention.

Claim 1 has been amended to more distinctly point out the claimed invention.

Regarding the indefiniteness of the term "amyloid fibril", Applicants respectfully point out that paragraphs 78-80 on pages 21 and 22 define the term. The properties of an amyloid fibril are set forth in paragraphs 78-80.

Regarding the indefiniteness of the term "an amyloid light chain polypeptide or whole light chain", Applicants respectfully point out that paragraph 11 on page 3 discusses AL amyloid which is due to deposition of the entire immunoglobulin light chain or a portion of the light chain.

Accordingly, the claims, as they stand, are not indefinite. Applicants respectfully request the withdrawal of the rejection.

**CONCLUSION**

In view of the foregoing claim amendments and accompanying remarks, Applicants respectfully request reconsideration and timely allowance of the pending claims. Should the Examiner feel that there are any issues outstanding after consideration of this response, the Examiner is invited to contact Applicants' undersigned representative to expedite prosecution.

If there are any additional fees due in connection with the filing of this response, please charge the fees to our Deposit Account No. 50-0310. If a fee is required for an extension of time

under 37 C.F.R. § 1.136 not accounted for above, such an extension is requested and the fee should also be charged to our Deposit Account.

Respectfully submitted,

**MORGAN, LEWIS & BOCKIUS LLP**

  
Sally P. Teng  
Reg. No. 45,397

Dated: October 25, 2002

**CUSTOMER NO. 009629**

**MORGAN, LEWIS & BOCKIUS LLP**  
1111 Pennsylvania Ave., N.W.  
Washington, D.C. 20004  
(202) 739-3000

**VERSION WITH MARKINGS TO SHOW CHANGES MADE**

Claim 1 has been amended as follows:

1. (Amended) A method of removing amyloid deposits from a **subject** [patient] comprising administering to the **subject** [patient] amyloid fibrils in an effective amount to generate an immune response, **wherein the immune response promotes** [~~that will promote~~] the removal of [*in vivo*] amyloid **deposits** [fibrils] from the patient.

Claim 2 has been amended as follows:

2. (Amended) **A** [~~The~~] method of claim 1, wherein the amyloid fibrils comprise[s] an **immunoglobulin** [~~amyloid~~] light chain polypeptide or a whole **immunoglobulin** light chain polypeptide.

Claim 3 has been amended as follows:

3. (Amended) A vaccine or pharmaceutical composition comprising [~~an~~] amyloid fibrils [~~and a carrier~~].